Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.
New dermal collaboration on XF-73
Destiny Pharma has announced a new clinical programme that is planned to start in China, led by its...
Read moreH1 2021 interims: still on track
Destiny's interim H1 2021 financial results were an upbeat and extensive update on the clinical...
Read moreXF-73 data maturing, like a fine wine
Destiny have released additional endpoint analyses after the positive headline announcement of the...
Read moreA glaring differential in validation
Recent transactions and the introduction of a new Act of the US Congress are further advancing the...
Read moreEncouraging AGM and M3 updates
Destiny’s recent announcement on the progress on its lead asset NTCD-M3 maintains the momentum that...
Read moreM3: another gem in the portfolio
With the recent announcement of the positive Phase 2b clinical study of XF-73 in the prevention of...
Read moreWhat a difference a year makes
Destiny has transformed its position, both in fundamental terms and in share price strength. A year...
Read more
The best possible scenario
Destiny has announced the top-line results of its Phase 2b clinical study of XF-73 in the...
Read more2021 starts well with XF-73 study fully recruited
Destiny has announced that the patient recruitment for its Phase 2b study, conducted under a US...
Read more
Competition for XF-73 moves aside, issue approved
Our previous note discussed Destiny’s acquisition of the Phase 3-ready NTCD M3 product for the...
Read more- Prev
- 1 of 3 pages
- Next
Register to be first
Get research on the companies that interest you straight to your inbox
